Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How A Biomarker Revived Synta’s Cancer Drug Elesclomol

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
Advertisement

Related Content

Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Emerging Phase III Data Validate Clinical Trial Design In Lupus
Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B

Topics

Advertisement
UsernamePublicRestriction

Register

PS004693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel